GTHX insider transaction filings
G1 Therapeutics, Inc. — 32 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-09-18. Screen GTHX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for GTHX between 2026-06-11 and 2026-09-09. The table below lists the most recent filings on record.
Recent Form 4 filings — G1 Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-09-18 | 4 | Malik Rajesh — Chief Medical Officer | Grant/award (A): 17,900 · Disposition to issuer (D): 89,762 · Code (U): 87,450 · Disposition to issuer (D): 74,500 (derivative) · Disposition to issuer (D): 35,700 (derivative) · Disposition to issuer (D): 57,333 (derivative) · +1 more | EDGAR |
| 2024-09-18 | 4 | Secor Alicia — Director | Disposition to issuer (D): 20,000 · Code (U): 10,000 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Bailey John E. (Jack) Jr. — President and CEO, Director | Grant/award (A): 181,400 · Disposition to issuer (D): 534,787 · Code (U): 196,287 · Disposition to issuer (D): 201,300 (derivative) · Disposition to issuer (D): 161,300 (derivative) | EDGAR |
| 2024-09-18 | 4 | Avagliano Mark — Chief Business Officer | Grant/award (A): 20,600 · Disposition to issuer (D): 236,610 · Code (U): 26,035 · Disposition to issuer (D): 89,400 (derivative) · Disposition to issuer (D): 41,100 (derivative) | EDGAR |
| 2024-09-18 | 4 | Lee Jacks — Director | Disposition to issuer (D): 10,000 · Code (U): 10,000 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Sharpless Norman — Director | Disposition to issuer (D): 20,000 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Flowers Cynthia Louise — Director | Disposition to issuer (D): 20,000 · Code (U): 15,889 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Nicholson Garry A — Director | Disposition to issuer (D): 20,000 · Code (U): 14,389 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Thomas Monica R. — Chief Legal & People Officer | Disposition to issuer (D): 138,151 · Code (U): 6,674 · Disposition to issuer (D): 55,875 (derivative) · Disposition to issuer (D): 150,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Umstead John W. V — Chief Financial Officer | Disposition to issuer (D): 168,387 · Code (U): 19,331 · Disposition to issuer (D): 74,500 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 100,000 (derivative) | EDGAR |
| 2024-09-18 | 4 | Perry Andrew — Chief Commercial Officer | Grant/award (A): 16,100 · Disposition to issuer (D): 114,482 · Code (U): 14,232 · Disposition to issuer (D): 67,050 (derivative) · Disposition to issuer (D): 32,100 (derivative) | EDGAR |
| 2024-09-18 | 4 | MURDOCK TERRY L — Chief Operating Officer | Grant/award (A): 17,900 · Disposition to issuer (D): 124,762 · Code (U): 21,150 · Disposition to issuer (D): 74,500 (derivative) · Disposition to issuer (D): 35,700 (derivative) | EDGAR |
| 2024-09-18 | 4 | MUIR GLENN P — Director | Disposition to issuer (D): 20,000 · Code (U): 185,358 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) | EDGAR |
| 2024-07-08 | 4 | Perry Andrew — Chief Commercial Officer | Sale (S): 1,337 @ $2.51 | EDGAR |
| 2024-07-08 | 4 | Malik Rajesh — Chief Medical Officer | Sale (S): 2,475 @ $2.51 | EDGAR |
| 2024-07-08 | 4 | Avagliano Mark — Chief Business Officer | Sale (S): 2,638 @ $2.51 | EDGAR |
| 2024-07-08 | 4 | Umstead John W. V — Chief Financial Officer | Sale (S): 527 @ $2.51 | EDGAR |
| 2024-07-08 | 4 | Bailey John E. (Jack) Jr. — President and CEO, Director | Sale (S): 7,662 @ $2.51 | EDGAR |
| 2024-07-08 | 4 | MURDOCK TERRY L — Chief Operating Officer | Sale (S): 2,475 @ $2.51 | EDGAR |
| 2024-07-03 | 4 | Perry Andrew — Chief Commercial Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2024-07-03 | 4 | Thomas Monica R. — Chief Legal & People Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2024-07-03 | 4 | Avagliano Mark — Chief Business Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2024-07-03 | 4 | Umstead John W. V — Chief Financial Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2024-07-03 | 4 | Bailey John E. (Jack) Jr. — President and CEO, Director | Grant/award (A): 105,000 @ $0 | EDGAR |
| 2024-07-03 | 4 | MURDOCK TERRY L — Chief Operating Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2024-06-14 | 4 | Sharpless Norman — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Secor Alicia — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Lee Jacks — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Flowers Cynthia Louise — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Nicholson Garry A — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | MUIR GLENN P — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Thomas Monica R. — Chief Legal & People Officer | Sale (S): 5,826 @ $4.27 | EDGAR |
Recent 8-K events — G1 Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-09-18 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2024-08-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-24 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2024-06-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GTHX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →